Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation

Wang, Z.; Shi, Bingyi; Qian, Yun; Cai, Ming; Wang, Q.

doi:10.1111/j.1365-2249.2008.03847.x

Cited by 35 publications

(23 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To ascertain a toxic effect of ATG on bone marrow progenitor cells, which remains a rare detectable circulating event, we probably need to explore more patients with the use of fresh samples to enhance analysis sensitivity and to shorten the delay following induction therapy to detect early variation in hematopoietic precursor cells. (19). Treg expansion has already been reported after ATG therapy.…”

Section: Discussionmentioning

confidence: 95%

ATG-Induced Accelerated Immune Senescence: Clinical Implications in Renal Transplant Recipients

Crépin

Carron

Roubiou

et al. 2015

American Journal of Transplantation

View full text Add to dashboard Cite

y These authors contributed equally to this work. Persistent ATG-induced CD4þ T cell lymphopenia is associated with serious clinical complications. We tested the hypothesis that ATG induces accelerated immune senescence in renal transplant recipients (RTR). Immune senescence biomarkers were analyzed at transplant and one-year later in 97 incident RTR À62 patients receiving ATG and 35 receiving anti-CD25 mAb (a-CD25). This consisted in: (i) thymic output; (ii) bone marrow renewal of CD34 þ hematopoietic progenitor cells (CD34 þ HPC) and lymphoid (l-HPC) and myeloid (m-HPC) progenitor ratio; (iii) T cell phenotype; and (iv) measurement of T cell relative telomere length (RTL) and telomerase activity (RTA). Clinical correlates were analyzed with a 3 year follow-up. Thymic output significantly decreased oneyear posttransplant in ATG-treated patients. ATG was associated with a significant decrease in l-HPC/m-HPC ratio. Late stage differentiated CD57 þ /CD28 À T cells increased in ATG-treated patients. One-year posttransplant T cell RTL and RTA were consequently lower in ATG-treated patients. ATG is associated with accelerated immune senescence. Increased frequency of late differentiated CD4 þ T cell frequency at transplantation tended to be predictive of a higher risk of subsequent opportunistic infections and of acute rejection only in ATG-treated patients but this needs confirmation. Considering pretransplant immune profile may help to select those patients who may benefit from ATG to prevent severe infections and acute rejection.

show abstract

Section: Discussionmentioning

confidence: 95%

ATG-Induced Accelerated Immune Senescence: Clinical Implications in Renal Transplant Recipients

Crépin

Carron

Roubiou

et al. 2015

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…Reduced expression of CD25 and Bcl‐2 in intra‐islet T reg cells suggests increased apoptosis as a cause of T reg dysfunction. Additionally, it has also been observed that administration of low dose IL‐2 promotes T reg cell survival and protects them from developing diabetes . The neutralization of circulating IL‐2 by anti‐IL‐2 monoclonal antibodies may trigger early onset diabetes and may trigger other cell mediated autoimmune diseases .…”

Section: Discussionmentioning

confidence: 99%

Is basiliximab induction, a novel risk factor for new onset diabetes after transplantation for living donor renal allograft recipients?

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Treatment with basiliximab in transplant patients can lead to a transient reduction of both Treg 47-49 and down-modulation of CD25 expression on Treg without deleting the cells or impairing their functions 50,51,52 . A recent study finds that donor-reactive Treg is minimally impacted in lung transplant patients after basiliximab induction 53 .…”

Section: Impact Of Approved Immunosuppressive Drugs On Tregmentioning

confidence: 99%

Impact of Immune-Modulatory Drugs on Regulatory T Cell

2016

View full text Add to dashboard Cite

Immunosuppression strategies that selectively inhibit effector T cells while preserving and even enhancing CD4+FOXP3+ regulatory T cells (Treg) permit immune self-regulation and may allow minimization of immunosuppression and associated toxicities. Many immunosuppressive drugs were developed before the identity and function of Treg were appreciated. A good understanding of the interactions between Treg and immunosuppressive agents will be valuable to the effective design of more tolerable immunosuppression regimens. This review will discuss preclinical and clinical evidence regarding the influence of current and emerging immunosuppressive drugs on Treg homeostasis, stability, and function as a guideline for the selection and development of Treg-friendly immunosuppressive regimens.

show abstract

Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation

Abstract: Summary CD4+ CD25 + forkhead box P3 (FoxP3) + regulatory T (Treg) cells are generated and play a key role in the induction and maintenance of transplant tolerance in organ recipients. It has been proposed that interleukin (

Cited by 35 publications

References 30 publications

ATG-Induced Accelerated Immune Senescence: Clinical Implications in Renal Transplant Recipients

ATG-Induced Accelerated Immune Senescence: Clinical Implications in Renal Transplant Recipients

Is basiliximab induction, a novel risk factor for new onset diabetes after transplantation for living donor renal allograft recipients?

Impact of Immune-Modulatory Drugs on Regulatory T Cell

Contact Info

Product

Resources

About